Novo Nordisk 14 jun 2026 Novo Nordisk’s CagriSema Breakthrough Expands Growth Story Beyond Diabetes and Obesity - simplywall.st
Novo Nordisk 12 jun 2026 Novo Nordisk identifies unauthorised data access from trials - Clinical Trials Arena
Novo Nordisk 12 jun 2026 Pharma giant Novo Nordisk discloses breach of clinical trials data - BleepingComputer
Novo Nordisk 11 jun 2026 Biopharma bites: Summit reverses on proposed raise, Novo Nordisk's cyberattack and Camurus' CRL - FirstWord Pharma
Novo Nordisk 11 jun 2026 Novo Nordisk flags patient data breach from some clinical trials in cyberattack - Reuters
Novo Nordisk 11 jun 2026 Novo reports data breach, tells clinical trial patients to 'remain vigilant' - Fierce Pharma
Novo Nordisk 8 jun 2026 Novo Nordisk reports Phase II data for zenagamtide in diabetes - Clinical Trials Arena
Novo Nordisk 8 jun 2026 Novo Nordisk broadens semaglutide case beyond weight loss - The Pharma Letter
Novo Nordisk 7 jun 2026 Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026 - PR Newswire
Novo Nordisk 5 jun 2026 Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes--presented at ADA 2026 - PR Newswire
Novo Nordisk 5 jun 2026 Veru (NASDAQ: VERU) Stock Price Surges Over 160% After Clinical Supply Deal With Novo Nordisk (NYSE: NVO) - foreignpolicyjournal.com
Novo Nordisk 4 jun 2026 Veru (VERU) surges 161.8% after disclosing Novo Nordisk Wegovy supply deal for obesity study - Quiver Quantitative
Novo Nordisk 4 jun 2026 This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection? - Stocktwits
Novo Nordisk 4 jun 2026 Veru Inc. Enters Clinical Supply Agreement with Novo Nordisk for Phase 2B Plateau Clinical Study - marketscreener.com